1 de 7 sur environ 7 communiqués.
FibroGen, Inc
SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with...
FibroGen, Inc
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
Equillium
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA)...
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy outcomes with open-label extension dosing at six months12-month 150 subject study with ACR/EULAR 2016 Total...
Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as high...
Ripley's Believe It or Not! Times Square
NEW YORK, July 29, 2015 (GLOBE NEWSWIRE) -- The train may have left the station… and it's arrived at Ripley's Believe It or Not! Times Square! The conductor has slammed on the breaks to this...
1 de 7 sur environ 7 communiqués.
